Trial · NCT00823836
Results by group334
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 334
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Mean Change From Week 0 (Baseline) in the Japanese Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score at the Final Assessment Point (FAP) (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole PR-Ropinirole PR | -10.8 | Standard Deviation 8.32 | scores on a scale | |
Mean Change From Week 0 (Baseline) in the Japanese Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score at the Final Assessment Point (FAP) (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole IR-Ropinirole PR | -11.0 | Standard Deviation 7.56 | scores on a scale | |
| Percentage of Responders on the Japanese UPDRS Part III Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole PR-Ropinirole PR | 30 percent responder | 66 | percentage of participants | |
| Percentage of Responders on the Japanese UPDRS Part III Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole IR-Ropinirole PR | 30 percent responder | 69 | percentage of participants | |
| Percentage of Responders on the Japanese UPDRS Part III Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole PR-Ropinirole PR | 20 percent responder | 81 | percentage of participants | |
| Percentage of Responders on the Japanese UPDRS Part III Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole IR-Ropinirole PR | 20 percent responder | 78 | percentage of participants | |
| Mean Change From Week 0 in the Japanese UPDRS Part I Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole PR-Ropinirole PR | -0.2 | Standard Deviation 1.25 | scores on a scale | |
| Mean Change From Week 0 in the Japanese UPDRS Part I Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole IR-Ropinirole PR | -0.3 | Standard Deviation 1.21 | scores on a scale | |
| Mean Change From Week 0 in the Japanese UPDRS Part II (at On) Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole PR-Ropinirole PR | -2.6 | Standard Deviation 3.69 | scores on a scale | |
| Mean Change From Week 0 in the Japanese UPDRS Part II (at On) Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole IR-Ropinirole PR | -2.9 | Standard Deviation 4.17 | scores on a scale | |
| Mean Change From Week 0 in the Japanese UPDRS Part II (at Off) Total Score at Week 24 in the Non-Inferiority Verification Phase | Ropinirole PR-Ropinirole PR | -4.7 | Standard Deviation 4.49 | scores on a scale | |
| Mean Change From Week 0 in the Japanese UPDRS Part II (at Off) Total Score at Week 24 in the Non-Inferiority Verification Phase | Ropinirole IR-Ropinirole PR | -3.8 | Standard Deviation 5.15 | scores on a scale | |
| Mean Change From Week 0 in the Japanese UPDRS Part IV Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole PR-Ropinirole PR | -0.6 | Standard Deviation 1.51 | scores on a scale | |
| Mean Change From Week 0 in the Japanese UPDRS Part IV Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase | Ropinirole IR-Ropinirole PR | -0.2 | Standard Deviation 1.68 | scores on a scale | |
| Japanese UPDRS Part I Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase | Ropinirole PR-Ropinirole PR | Week 0; n=156, 146 | 0.9 | Standard Deviation 1.30 | scores on a scale |
| Japanese UPDRS Part I Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase | Ropinirole IR-Ropinirole PR | Week 0; n=156, 146 | 1.1 | Standard Deviation 1.35 | scores on a scale |
| Japanese UPDRS Part I Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase | Ropinirole PR-Ropinirole PR | FAP; n=151, 142 | 0.7 | Standard Deviation 1.34 | scores on a scale |
| Japanese UPDRS Part I Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase | Ropinirole IR-Ropinirole PR | FAP; n=151, 142 | 0.8 | Standard Deviation 1.50 | scores on a scale |
| Japanese UPDRS Part II (at On) Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase | Ropinirole PR-Ropinirole PR | Week 0; n=156, 146 | 7.7 | Standard Deviation 5.51 | scores on a scale |
| Japanese UPDRS Part II (at On) Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase | Ropinirole IR-Ropinirole PR | Week 0; n=156, 146 | 7.6 | Standard Deviation 5.87 | scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00823836/results